AU2009304235B2 - Co-crystals of tramadol and NSAIDs - Google Patents

Co-crystals of tramadol and NSAIDs Download PDF

Info

Publication number
AU2009304235B2
AU2009304235B2 AU2009304235A AU2009304235A AU2009304235B2 AU 2009304235 B2 AU2009304235 B2 AU 2009304235B2 AU 2009304235 A AU2009304235 A AU 2009304235A AU 2009304235 A AU2009304235 A AU 2009304235A AU 2009304235 B2 AU2009304235 B2 AU 2009304235B2
Authority
AU
Australia
Prior art keywords
crystal
tramadol
naproxen
crystals
physiologically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2009304235A
Other languages
English (en)
Other versions
AU2009304235A1 (en
Inventor
Jordi Benet Buchholz
Helmut Heinrich Buschmann
Jordi Carles Ceron Bertran
Carlos Ramon Plata Salaman
Lluis Sola Carandell
Nicolas Tesson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Esteve Pharmaceuticals SA
Original Assignee
Esteve Pharmaceuticals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esteve Pharmaceuticals SA filed Critical Esteve Pharmaceuticals SA
Publication of AU2009304235A1 publication Critical patent/AU2009304235A1/en
Application granted granted Critical
Publication of AU2009304235B2 publication Critical patent/AU2009304235B2/en
Assigned to ESTEVE PHARMACEUTICALS, S.A. reassignment ESTEVE PHARMACEUTICALS, S.A. Request to Amend Deed and Register Assignors: LABORATORIOS DEL DR. ESTEVE, S.A.
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/74—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU2009304235A 2008-10-17 2009-10-16 Co-crystals of tramadol and NSAIDs Ceased AU2009304235B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20080384012 EP2177215A1 (en) 2008-10-17 2008-10-17 Co-crystals of tramadol and NSAIDs
EP08384012.4 2008-10-17
PCT/EP2009/007451 WO2010043412A1 (en) 2008-10-17 2009-10-16 Co-crystals of tramadol and nsaids

Publications (2)

Publication Number Publication Date
AU2009304235A1 AU2009304235A1 (en) 2010-04-22
AU2009304235B2 true AU2009304235B2 (en) 2015-05-07

Family

ID=40673614

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009304235A Ceased AU2009304235B2 (en) 2008-10-17 2009-10-16 Co-crystals of tramadol and NSAIDs

Country Status (27)

Country Link
US (10) US20110257134A1 (enExample)
EP (2) EP2177215A1 (enExample)
JP (1) JP5645830B2 (enExample)
KR (1) KR101679400B1 (enExample)
CN (1) CN102186465B (enExample)
AU (1) AU2009304235B2 (enExample)
BR (1) BRPI0920358A2 (enExample)
CA (1) CA2737754C (enExample)
CY (1) CY1118374T1 (enExample)
DK (1) DK2349238T3 (enExample)
ES (1) ES2603962T3 (enExample)
HR (1) HRP20161526T1 (enExample)
HU (1) HUE030976T2 (enExample)
IL (1) IL211785A (enExample)
IN (1) IN2012DN01435A (enExample)
LT (1) LT2349238T (enExample)
MX (1) MX336318B (enExample)
MY (1) MY156285A (enExample)
NZ (1) NZ591873A (enExample)
PL (1) PL2349238T3 (enExample)
PT (1) PT2349238T (enExample)
RU (1) RU2599717C2 (enExample)
SI (1) SI2349238T1 (enExample)
SM (1) SMT201600439B (enExample)
UA (1) UA109534C2 (enExample)
WO (1) WO2010043412A1 (enExample)
ZA (1) ZA201102762B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2177215A1 (en) * 2008-10-17 2010-04-21 Laboratorios Del. Dr. Esteve, S.A. Co-crystals of tramadol and NSAIDs
EP2392319A1 (en) 2010-06-04 2011-12-07 Laboratorios Del. Dr. Esteve, S.A. Pharmaceutical compositions of co-crystals of tramadol and coxibs
KR20130129070A (ko) * 2010-07-12 2013-11-27 융신 파마슈티칼 인더스트리얼 컴파니 리미티드 트라마돌의 디클로페낙 염
DE102010063609A1 (de) * 2010-12-20 2012-06-21 Awd.Pharma Gmbh & Co. Kg Neue Multikomponentenkristalle aus ([2-Amino-6-(4-fluoro-benzylamino)-pyridin-3yl)-carbamidsäureethylester und einer Arylpropionsäure
KR101888852B1 (ko) 2011-12-02 2018-09-21 삼성전자주식회사 휴대용 단말기에서 다이버시티 서비스를 제공하기 위한 장치 및 방법
GB201222287D0 (en) * 2012-12-11 2013-01-23 Ct For Process Innovation Ltd Methods for making active crystalline materials
ITMI20130210A1 (it) * 2013-02-14 2014-08-15 Menarini Lab Composizioni farmaceutiche contenenti dexketoprofene e tramadolo
RU2542100C1 (ru) * 2013-12-24 2015-02-20 Федеральное государственное бюджетное учреждение науки Институт химии растворов им. Г.А. Крестова Российской Академии Наук (ИХС РАН) Сокристаллическая форма теофиллина с дифлунисалом или диклофенаком
WO2016116942A1 (en) 2015-01-20 2016-07-28 Anlon Chemical Research Organization Novel pharmaceutical compounds comprising ticagrelor with salts of aspirin
CN104592009B (zh) * 2015-02-09 2017-02-22 黑龙江大学 萘普生药物共晶及其制备方法
US9693949B1 (en) * 2015-12-22 2017-07-04 Revogenex Ireland Ltd Intravenous administration of tramadol
MX2016006464A (es) * 2016-05-18 2017-11-17 Laboratorios Liomont S A De C V Composicion farmaceutica de una combinacion de clorhidrato de tramadol-etoricoxib para el tratamiento del dolor.
JP2020514337A (ja) * 2017-03-08 2020-05-21 インターセプト ファーマシューティカルズ， インコーポレイテッド オベチコール酸の結晶形態
WO2019122982A1 (en) 2017-12-21 2019-06-27 Grünenthal GmbH Pharmaceutical combination in a bilayer tablet form comprising ketorolac tromethamine and tramadol hydrochloride, and its use in pain treatment
WO2019130049A1 (en) 2017-12-29 2019-07-04 Grünenthal GmbH Pharmaceutical combination comprising extended-release tramadol hydrochloride and immediate-release etoricoxib, and its use for the treatment of pain
EP3814353A4 (en) 2018-05-31 2021-11-24 The Royal Institution for the Advancement of Learning / McGill University PHARMACEUTICAL SALTS / CO CRYSTALS OF PENTOXIFYLLINE, CLONIDINE AND LINSIDOMINE WITH COFFEE ACID, PROTOCATECHU ACID OR ALPHA-LIPONIC ACID AND THEIR USE FOR THE TREATMENT OF PAIN
US20210317086A1 (en) * 2018-08-20 2021-10-14 Mylan Laboratories Limited Tramadol HBR-Celecoxib Co-Crystal
WO2020121326A1 (en) 2018-12-13 2020-06-18 Mylan Laboratories Limited Amorphous (rac)-tramadol.hcl-celecoxib (1:1)
CA3137381A1 (en) * 2019-05-14 2020-11-19 Esteve Pharmaceuticals, S.A. Use of co-crystals of tramadol and celecoxib for treating pain while reducing the abuse liability of tramadol
EP3842408A1 (en) 2019-12-23 2021-06-30 Dompé farmaceutici S.p.A. Co-crystal of ketoprofen and its preparation, pharmaceutical compositions comprising the same and uses thereof
EP3907214A1 (en) 2020-05-04 2021-11-10 Dompe' Farmaceutici S.P.A. Co-crystal of ketoprofen, lysine and gabapentin, pharmaceutical compositions and their medical use
EP4169903A1 (en) * 2021-10-25 2023-04-26 Dompe' Farmaceutici S.P.A. Co-crystals of nonsteroidal anti-inflammatory drugs, lysine and gabapentin, pharmaceutical compositions and their medical use
KR20240027436A (ko) * 2022-08-23 2024-03-04 대원제약주식회사 펠루비프로펜 및 트라마돌의 이온결합 화합물, 이를 포함하는 조성물, 및 이의 제조 방법
CN116492349B (zh) * 2023-04-11 2025-09-09 东南大学 奥沙普秦和异烟肼低共熔物、药物组合物及其制备方法
KR20240158668A (ko) * 2023-04-27 2024-11-05 대원제약주식회사 펠루비프로펜 및 트라마돌을 포함하는 진통용 약학적 조성물

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0546676A1 (en) * 1991-10-30 1993-06-16 Mcneilab, Inc. Composition comprising a tramadol material and a non-steroidal anti-inflammatory drug
US20080031950A1 (en) * 2007-04-27 2008-02-07 Nectid Inc. Novel anelgesic combination
WO2008064854A1 (de) * 2006-11-28 2008-06-05 Grünenthal GmbH Arzneimittelzubereitung von tramadol und acetaminophen
WO2009018959A1 (en) * 2007-08-07 2009-02-12 Laboratorios Del Dr. Esteve S.A. Salts of tramadol and naproxen and their crystal forms in the treatment of pain

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3652589A (en) 1967-07-27 1972-03-28 Gruenenthal Chemie 1-(m-substituted phenyl)-2-aminomethyl cyclohexanols
DE122004000032I2 (de) 1991-09-06 2006-02-09 Mcneilab Inc Zusammensetzung die eine Tramadol-Verbindung und Acetaminophen enth{lt, und ihre Verwendung
US5516803A (en) 1991-10-30 1996-05-14 Mcneilab, Inc. Composition comprising a tramadol material and a non-steroidal anti-inflammatory drug
US5474995A (en) 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5466823A (en) 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
CA2277954A1 (en) 1993-11-30 1995-06-08 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation
US5633272A (en) 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
UA57002C2 (uk) 1995-10-13 2003-06-16 Мерк Фросст Кенада Енд Ко./Мерк Фросст Кенада Енд Сі. Похідне (метилсульфоніл)феніл-2-(5н)-фуранону, фармацевтична композиція та спосіб лікування
GEP20032998B (en) 1996-04-12 2003-06-25 Searle & Co Substituted Benzenesulfonamide Derivatives as Prodrugs of Cox-2 Inhibitors
SI0912518T1 (en) 1996-07-18 2003-12-31 Merck Frosst Canada & Co. Substituted pyridines as selective cyclooxygenase-2 inhibitors
US5861419A (en) 1996-07-18 1999-01-19 Merck Frosst Canad, Inc. Substituted pyridines as selective cyclooxygenase-2 inhibitors
CO4960662A1 (es) 1997-08-28 2000-09-25 Novartis Ag Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados
RS49982B (sr) 1997-09-17 2008-09-29 Euro-Celtique S.A., Sinergistička analgetička kombinacija analgetičkog opijata i inhibitora ciklooksigenaze-2
NZ513924A (en) * 1999-03-01 2001-09-28 Ortho Mcneil Pharm Inc Composition comprising a tramadol material and a selective cox-2 inhibitor drug
DE19927688A1 (de) 1999-06-17 2000-12-21 Gruenenthal Gmbh Mehrschichttablette zur Verabreichung einer fixen Kombination von Tramadol und Diclofenac
DE10108122A1 (de) 2001-02-21 2002-10-02 Gruenenthal Gmbh Arzneimittel auf Basis von Tramadol
CN1473035B (zh) * 2001-07-27 2012-07-18 安斯泰来制药有限公司 含有口腔内迅速崩解片剂用缓释微粒的组合物及其制造方法
US7927613B2 (en) * 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
US7790905B2 (en) 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
WO2004078163A2 (en) * 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
PT1478366E (pt) 2002-02-19 2009-03-10 Adcock Ingram Ltd Combinações farmacêuticas de meloxicam, fosfato de codeína e paracetamol
ATE370264T1 (de) 2002-07-17 2007-09-15 Soitec Silicon On Insulator Verfahren zur herstellung von substraten, insbesondere für die optik, elektronik und optoelektronik
CN1245968C (zh) 2002-10-09 2006-03-22 新疆特丰药业股份有限公司 一种萘普生钠缓释片剂的制备方法
US7390505B2 (en) 2003-01-31 2008-06-24 Elan Pharma International, Ltd. Nanoparticulate topiramate formulations
US20060172006A1 (en) * 2003-10-10 2006-08-03 Vincent Lenaerts Sustained-release tramadol formulations with 24-hour clinical efficacy
JP2007516259A (ja) 2003-12-09 2007-06-21 メッドクリスタルフォームズ、エルエルシー 活性剤との混合相共結晶の調製方法
US8216610B2 (en) * 2004-05-28 2012-07-10 Imaginot Pty Ltd. Oral paracetamol formulations
WO2008085674A1 (en) 2007-01-04 2008-07-17 Transform Pharmaceuticals, Inc. Pharmaceutical compositions comprising celecoxib co-crystals
JP5757864B2 (ja) 2008-05-20 2015-08-05 ニューロジェシックス， インコーポレイテッド 水溶性アセトアミノフェン類似体
EA016904B1 (ru) 2008-09-06 2012-08-30 Бионевия Фармасьютикалс, Инк. Новый холиновый сокристалл эпалрестата
EP2177215A1 (en) * 2008-10-17 2010-04-21 Laboratorios Del. Dr. Esteve, S.A. Co-crystals of tramadol and NSAIDs
JP5399564B2 (ja) 2009-10-16 2014-01-29 ラボラトリオス・デル・デエレ・エステベ・エセ・ア トラマドールとコキシブとの共結晶
EP2586432A3 (en) * 2009-10-16 2013-07-10 Laboratorios Del Dr. Esteve, S.A. Co-crystals of Tramadol and NSAIDs like Coxibs
EP2311446A1 (en) 2009-10-16 2011-04-20 Laboratorios Del. Dr. Esteve, S.A. Compositions comprising Tramadol and Celecoxib in the treatment of pain
US20130195996A1 (en) * 2010-05-07 2013-08-01 Carefusion 2200, Inc. Method of producing pleurodesis
EP2392319A1 (en) * 2010-06-04 2011-12-07 Laboratorios Del. Dr. Esteve, S.A. Pharmaceutical compositions of co-crystals of tramadol and coxibs
CA3137381A1 (en) * 2019-05-14 2020-11-19 Esteve Pharmaceuticals, S.A. Use of co-crystals of tramadol and celecoxib for treating pain while reducing the abuse liability of tramadol

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0546676A1 (en) * 1991-10-30 1993-06-16 Mcneilab, Inc. Composition comprising a tramadol material and a non-steroidal anti-inflammatory drug
WO2008064854A1 (de) * 2006-11-28 2008-06-05 Grünenthal GmbH Arzneimittelzubereitung von tramadol und acetaminophen
US20080031950A1 (en) * 2007-04-27 2008-02-07 Nectid Inc. Novel anelgesic combination
WO2009018959A1 (en) * 2007-08-07 2009-02-12 Laboratorios Del Dr. Esteve S.A. Salts of tramadol and naproxen and their crystal forms in the treatment of pain

Also Published As

Publication number Publication date
US20200171055A1 (en) 2020-06-04
US9393220B2 (en) 2016-07-19
BRPI0920358A2 (pt) 2020-08-11
US11478488B2 (en) 2022-10-25
IN2012DN01435A (enExample) 2015-06-05
US20150196504A1 (en) 2015-07-16
US9012440B2 (en) 2015-04-21
LT2349238T (lt) 2016-12-27
WO2010043412A1 (en) 2010-04-22
US10238668B2 (en) 2019-03-26
US8598152B2 (en) 2013-12-03
NZ591873A (en) 2012-12-21
DK2349238T3 (en) 2016-12-12
US20140350110A1 (en) 2014-11-27
PL2349238T3 (pl) 2017-06-30
KR101679400B1 (ko) 2016-11-24
US20120172398A1 (en) 2012-07-05
EP2349238B1 (en) 2016-08-24
US20140057879A1 (en) 2014-02-27
ZA201102762B (en) 2011-12-28
JP5645830B2 (ja) 2014-12-24
US10548909B2 (en) 2020-02-04
HUE030976T2 (en) 2017-06-28
UA109534C2 (uk) 2015-09-10
CN102186465B (zh) 2015-09-16
US20190231800A1 (en) 2019-08-01
CA2737754A1 (en) 2010-04-22
AU2009304235A1 (en) 2010-04-22
US20170027965A1 (en) 2017-02-02
ES2603962T3 (es) 2017-03-02
MY156285A (en) 2016-01-29
RU2011119608A (ru) 2012-11-27
JP2012505847A (ja) 2012-03-08
EP2177215A1 (en) 2010-04-21
CA2737754C (en) 2016-09-20
EP2349238A1 (en) 2011-08-03
MX2011003612A (es) 2011-05-10
US20110257134A1 (en) 2011-10-20
RU2599717C2 (ru) 2016-10-10
US20150196503A1 (en) 2015-07-16
SI2349238T1 (sl) 2017-01-31
PT2349238T (pt) 2016-11-24
SMT201600439B (it) 2017-01-10
US10245276B2 (en) 2019-04-02
MX336318B (es) 2016-01-14
KR20110069860A (ko) 2011-06-23
CN102186465A (zh) 2011-09-14
US20170000806A1 (en) 2017-01-05
IL211785A0 (en) 2011-06-30
HRP20161526T1 (hr) 2016-12-16
CY1118374T1 (el) 2017-06-28
IL211785A (en) 2016-07-31

Similar Documents

Publication Publication Date Title
CA2737754C (en) Co-crystals of tramadol and nsaids
US8501802B2 (en) Co-crystals of duloxetine and COX-INHIBITORs for the treatment of pain
US20230057884A1 (en) Co-crystals of tramadol and coxibs
US8168679B2 (en) Salts of Tramadol and Naproxen and their crystal forms in the treatment of pain
US20110105443A1 (en) Salts of memantine and cox-inhibitors and their crystal form in the treatment of pain
WO2011015360A1 (en) Pharmaceutical compounds of o-desmethyl-tramadol and cox-inhibitors
RU2547830C2 (ru) Сокристаллы трамадола и коксибов
WO2010069561A1 (en) Cocrystals of tramadol and paracetamol
HK1160035B (en) Co-crystals of tramadol and nsaids

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
HB Alteration of name in register

Owner name: ESTEVE PHARMACEUTICALS, S.A.

Free format text: FORMER NAME(S): LABORATORIOS DEL DR. ESTEVE, S.A.

MK14 Patent ceased section 143(a) (annual fees not paid) or expired